Sylvia Adams

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

Peter Schmid, Sylvia Adams, Hope S. Rugo et al. · New England Journal of Medicine · 2018 · 4.4K citations · Full text

Medicine, Oncology, Pharmacology +17

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

Roberto Salgado, Carsten Denkert, Sandra Demaria et al. · Annals of Oncology · 2014 · 3.1K citations · Full text

Medicine, Immunology, Oncology +16

Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199

Sylvia Adams, Robert J. Gray, Sandra Demaria et al. · Journal of Clinical Oncology · 2014 · 1.3K citations · Full text

Medicine, Immunology, Oncology +17

Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

Peter Schmid, Hope S. Rugo, Sylvia Adams et al. · The Lancet Oncology · 2019 · 1.2K citations

Medicine, Oncology, Pharmacology +14

Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers

Sherene Loi, Damien Drubay, Sylvia Adams et al. · Journal of Clinical Oncology · 2019 · 891 citations · Full text

Medicine, Biostatistics, Oncology +17